Blockchain Registration Transaction Record

Citius Pharma Receives Approval for Business Combination with TenX Keane, Forming Citius Oncology, Inc.

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) receives approval for a business combination with TenX Keane Acquisition (NASDAQ: TENK), forming Citius Oncology, Inc. The new company will focus on developing and commercializing novel targeted oncology therapies, with LYMPHIR as the first drug to go to market.

This news matters as it highlights Citius Pharmaceuticals' strategic move to unlock value for shareholders through the formation of Citius Oncology, Inc. The development and commercialization of new targeted oncology therapies, starting with LYMPHIR, could have a significant impact on the treatment of T-cell lymphomas, potentially benefiting patients and investors alike.